


Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/93,721
				Filing Date	August 4, 2001
				First Named Inventor	HU et al.
				Group Art Unit	1647
				Examiner Name	Unassigned
Sheet	1	of	9	Attorney Docket Number	PF112P3D1C1

RECEIVED
FEB 04 2002
TECH CENTER 1800/2900

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
M	AA	5,633,147		Meissner et al.	05-27-1999	
	AB	5,283,354		Lemischka	02-01-1994	
	AC	5,240,848		Keck et al.	08-31-1993	
	AD	5,234,908		Szabo et al.	08-10-1993	
	AE	5,194,596		Tischer et al.	03-16-1993	
	AF	5,861,301		Terman et al.	01-19-1999	
	AG	5,840,693		Eriksson et al.	11-24-1999	
	AH	5,073,492		Chen et al.	12-17-1991	
	AI	5,219,739		Tischer et al.	06-15-1993	
	AJ	5,326,695		Andersson et al.	07-05-1994	
	AK	5,607,918		Eriksson et al.	03-04-1997	
	AL	5,776,755		Alitalo et al.	07-07-1998	
	AM	08/510132			08/1995	
	AN	08/585895			01/1996	
	AO	08/601132			02/1996	
	AP	08/671573			06/1996	
	AQ	60/003491			09/1995	
	AR	08/554374			11/1995	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
M	AS		99/46364		Human Genome Sciences, Inc.	09-16-1999
	AT		98/33917		Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	06-08-1998
	AU		98/07832		Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. Oy	02-26-1998

Examiner Signature		Date Considered	7-15-03
--------------------	--	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	HU et al.
				Group Art Unit	1647
				Examiner Name	Unassigned
Sheet	2	of	9	Attorney Docket Number	PF112P3D1C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ²	Number ³	Kind Code ⁴ (if known)		
<i>ML</i>	AV		96/39515		Human Genome Sciences, Inc.	12-12-1996
	AW		96/05856		Human Genome Sciences, Inc.	02-29-1996
	AX		95/24414		Human Genome Sciences, Inc.	09-14-1995
	AY		95/19985		Human Genome Sciences, Inc.	07-27-1995
	AZ		92/14748		American Cyanamid Co.	09-03-1992
	BA		9-403464		Human Genome Sciences, Inc.	01-31-1996
	BB		99/21590		Merck & Co.	05-06-1999
	BC		99/08522		Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	02-25-1999
	BD		98/56936		Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	12-17-1998
	BE		98/49300		Collateral Therapeutics	11-05-1998
	BF		98/39035		The Wistar Institute of Anatomy & Biology	09-11-1998
	BG		98/24811		Zymogenetics, Inc.	06-11-1998
	BH		98/06844		Human Genome Sciences, Inc.	02-19-1998
	BI		710696		Genentech, Inc.	09-30-1999
	BJ		0-476983		Bayne et al.	03-25-1992
	BK		0-506477		Bayne et al.	09-30-1992
	BL		97/05250		University of Helsinki	02-13-1997
	BM		97/09427		Genentech, Inc.	03-13-1997
	BN		97/17442		Immunex Corporation	05-15-1997

Examiner Signature	<i>Lachse</i>	Date Considered	2-15-03
--------------------	---------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

RECEIVED
 FEB 0 4 2003
 TECH CENTER 1600/2900

O I P E J C I T Y
 JAN 25 2002
 PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	HU et al.
				Group Art Unit	1647
				Examiner Name	Unassigned
Sheet	3	of	9	Attorney Docket Number	PF112P3D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M	BQ	ACHEN <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci. (USA)</i> , 95(2): 548-553 (1998).	
	BP	ALDERSON, et al. (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. <i>Keystone Symposia, Ocular Cell and Molecular Biology</i> , 202. (Abstract provided)	
	BQ	ANDERSSON <i>et al.</i> , "Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF," <i>J. Biol. Chem.</i> , 267(16): 11260-11266 (1992).	
	BR	ANDERSSON W.F., "Human gene therapy," <i>Science</i> , 256:808-813 (1992).	
	BS	Aprelikova <i>et al.</i> , "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter," <i>Cancer Research</i> , 52:746-748 (1992).	
	BT	DIGNAM <i>et al.</i> , "Balbiani ring 3 in <i>chironomus tentans</i> encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar," <i>Gene</i> 88:133-140 (1990).	
	BU	FERRARA <i>et al.</i> , "Molecular and biological properties of the vascular endothelial growth factor family of proteins," <i>Endocrine Rev.</i> 13(1): 18-32 (1992).	
	BV	FINNERTY <i>et al.</i> , "Molecular cloning of murine FLT and FLT4," <i>Oncogene</i> 8(11): 2293-2298 (1993).	
	BW	HELDIN <i>et al.</i> , "Structure of platelet-derived growth factor: implications for functional properties," <i>Growth Factors</i> 8:245-252 (1993).	
	BX	EICHMANN <i>et al.</i> , "Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors," <i>Development</i> 125(4): 743-752 (1998).	
	BY	PAJUSOLA <i>et al.</i> , "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines," <i>Cancer Research</i> 52:5738-5743 (1992).	
	BZ	LEUNG <i>et al.</i> , "Vascular endothelial growth factor is a secreted angiogenic mitogen," <i>Science</i> 246:1306-1309 (1989).	
	CA	BREIER <i>et al.</i> , "Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation," <i>Development</i> 114:521-532 (1992).	
	CB	BELL <i>et al.</i> , "Human epidermal growth factor precursor: cDNA sequence, expression <i>in vitro</i> and gene organization," <i>Nucl. Acids Res.</i> 14(21): 8427-8446 (1986).	
	CC	BERSE <i>et al.</i> , Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors," <i>Mol. Biol. Cell.</i> 3:211-220 (1992).	

Examiner Signature		Date Considered	7-15-03
--------------------	--	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box



PTO/SB/08 (08/00)

Approved for use through 10/31/2002. OMB 0651-005
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	HU et al.
				Group Art Unit	1647
				Examiner Name	Unassigned
Sheet	4	of	9	Attorney Docket Number	PF112P3D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
BL	CD	BETSHOLTZ <i>et al.</i> , "cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines," <i>Nature</i> 320:695-699 (1986).			
	CE	CLAFFEY <i>et al.</i> , "Vascular endothelial growth factor," <i>J. Biol. Chem.</i> 267(23): 16317-16322 (1992).			
	CF	CORSON <i>et al.</i> , "Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end," <i>Genomics</i> 17:476-484 (1993).			
	CG	FERRARA <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cellular Biochemistry</i> 47:211-218 (1991).			
	CH	GEORGE <i>et al.</i> , "Current Methods in Sequence Comparison and Analysis," <i>Macromolecular Seq. and Syn. Selected Meth - Application</i> (Alan R. Liss), pp. 127-149 (1988).			
	CI	HU <i>et al.</i> , "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells," <i>FASEB J.</i> 11:498-504 (1997).			
	CJ	JOUKOV <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> 15(2): 290-298 (1996).			
	CK	JOUKOV <i>et al.</i> , "Proteolytic processing regulates receptor specificity and activity of VEGF-C," <i>EMBO J.</i> 16(13): 3898-3911 (1997).			
	CL	KAIPAINEN <i>et al.</i> , "The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells," <i>J. Exp. Med.</i> 178:2077-2088 (1993).			
	CM	KECK <i>et al.</i> , "Vascular permeability factor, an endothelial cell mitogen related to PDGF," <i>Science</i> 246: 1309 (1989).			
	CN	KINGSLEY, D., "The TGF- β superfamily: new members, new receptors, and new genetic tests of function in different organisms," <i>Genes & Development</i> 8: 133-146 (1994).			
	CO	KUKK <i>et al.</i> , "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development," <i>Development</i> 122: 3829-37 (1996).			
	CP	LEE <i>et al.</i> , "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4," <i>Proc. Natl. Acad. Sci. (USA)</i> , 93:1988-1992 (1996).			
	CQ	MAGLIONE <i>et al.</i> , "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-931 (1993).			

Examiner Signature		Date Considered	9-15/03
--------------------	--	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900



Please type a plus sign (+) inside this box



PTO/SB/08 (0-000)

Approved for use through 10/31/2002. OMB 0651-0037
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 9

Complete if Known

Application Number	09/935,726
Filing Date	August 24, 2001
First Named Inventor	HU et al.
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	PF112P3D1C1

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CR		MAGLIONE <i>et al.</i> , "Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9267-9271 (1991).	
CS		MASSAGUE, J., "The transforming growth factor-beta family," <i>Annu. Rev. Cell Biol.</i> 6:597-641 (1990).	
CT		MATTHEWS <i>et al.</i> , "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to <i>c-kit</i> ," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9026-9030 (1991).	
CU		MILLAUER <i>et al.</i> , "High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> 72:835-846 (1993).	
CV		MILLAUER <i>et al.</i> , "Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant," <i>Nature</i> 367:576-579 (1994).	
CW		OLTVAI <i>et al.</i> , "Bcl-2 heterodimerizes <i>in vivo</i> with a conserved homolog, bax, that accelerates programmed cell death," <i>Cell</i> 74:609-619 (1993).	
CX		PAULSSON <i>et al.</i> , "The balbani ring 3 gene in <i>chironomus tentans</i> has a diverged repetitive structure split by many introns," <i>J. Mol. Biol.</i> 211:331-349 (1990).	
CY		PAJUSOLA <i>et al.</i> , "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts," <i>Oncogene</i> 8:2931-2937 (1993).	
CZ		TISCHER <i>et al.</i> , "Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family," <i>Biochem. & Biophys. Res. Comms.</i> 165(3): 1198-1206 (1989).	
DA		TANAKA <i>et al.</i> , "DNA sequence encoding the amino-terminal region of the human <i>c-src</i> protein: implications of sequence divergence among <i>src</i> -type kinase oncogenes," <i>Mol. Cell Biol.</i> 7(5): 1978-1983 (1987).	
DB		TERMAN <i>et al.</i> , "Identification of a new endothelial cell growth factor receptor tyrosine kinase," <i>Oncogene</i> 6:1677-1683 (1991).	
DC		TERMAN <i>et al.</i> , "Identification of the <i>kdr</i> tyrosine kinase as a receptor for vascular endothelial cell growth factor," <i>Biochem. Biophys. Res. Commun.</i> 187(3): 1579-1586 (1992).	
DD		TSUJIMOTO <i>et al.</i> , "Analysis of the structure, transcripts, and protein products of <i>bcl-2</i> , the gene involved in human follicular lymphoma," <i>Proc. Natl. Acad. Sci. (USA)</i> , 83:5214-5218 (1986).	
DE		TISCHER <i>et al.</i> , "The Human Gene for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> 266(18): 11947-11954 (1991).	
DF		FRIEDMAN, T., "A brief history of gene therapy," <i>Nat. Genetics</i> 2:93-98 (1992).	

Examiner Signature	<i>Quarrel</i>	Date Considered	9/15/02
--------------------	----------------	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231



Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number 09/935,726
Filing Date August 24, 2001
First Named Inventor HU et al.
Group Art Unit 1647
Examiner Name Unassigned
Attorney Docket Number PF112P3D1C1

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AK	DG	WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of ischemic heart disease," <i>Am. J. Med. Sci.</i> 306(2): 129-136 (1993).	
	DH	HOCKEL <i>et al.</i> , "Therapeutic angiogenesis," <i>Arch. Surg.</i> 128:423-429 (1993).	
	DI	GUZMAN <i>et al.</i> , "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> 73:1202-1207 (1993).	
	DJ	BELLOMO <i>et al.</i> , "Mice Lacking the Vascular Endothelial Growth Factor-B Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia," <i>Circ. Research</i> 89(2): e29-e35 (2000).	
	DK	COCKERILL <i>et al.</i> , "Angiogenesis: Models and Modulators" <i>Intl. Rev. Cytology</i> 159:113-160 (1995).	
	DL	GAMBLE <i>et al.</i> , "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," <i>J. Cell. Bio.</i> 121(4): 931-943 (1993).	
	DM	GOLDSPIEL <i>et al.</i> , "Human Gene Therapy," <i>Clinical Pharmacy</i> 12: 488-505 (1993).	
	DN	GRIMMOND <i>et al.</i> , "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor," <i>Genome Research</i> 6:124-131 (1996).	
	DO	HYDE <i>et al.</i> , "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," <i>Nature</i> 362: 250-255 (1993).	
	DP	KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> 262:117-119 (1993).	
	DQ	KOLODKA <i>et al.</i> , "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes in Vivo," <i>Somatic Cell and Molecular Genetics</i> 19(5): 491-497 (1993).	
	DR	LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129	
AK	DS	SHIBUYA <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 519-524 (1990).	
	DT	SILINS <i>et al.</i> , "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene," <i>Biochem. Biophys. Res. Comm.</i> 230: 413-418 (1997).	
	DU	STEWART <i>et al.</i> , "Insulin delivery by somatic cell gene therapy," <i>J of Mol. Endocrinology</i> 11: 335-341 (1993).	
	DV	TOWNSON <i>et al.</i> , "Characterization of the Murine VEGF-Related Factor Gene," <i>Biochem. & Biophys. Res. Comm.</i> 220: 922-928 (1996).	
	DW	WALSH <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204: 289-300.	
	DX	YOUREY, et al. (2000) Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells. <i>J. Neuroscience</i> , 20: 6781 - 6788.	

Examiner Signature


Date Considered

9.15.02

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box



PTO/SB/08 (08-2001)
Approved for use through 10/31/2002. OMB 0651-0061

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/935,726
Filing Date	August 24, 2001
First Named Inventor	HU et al.
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	PF112P3D1C1

Sheet 7 of 9

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PC	DY	YOUREY, et al. (1999) Vascular Endothelial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells In Vitro. Soc. Cell Biology, 227. (Abstract provided)	
	DZ	GenBank Accession No. X68203, APRELIKOVA et al., "H.sapiens mRNA for FLT4, class III receptor tyrosine kinase," November 30, 1993.	
	EA	GenBank Accession No. M95200, CLAFFEY et al., "Mouse vascular endothelial growth factor mRNA, complete cds," April 27, 1993.	
	EB	GenBank Accession No. M24160, DIGNAM et al., "C.tentans 185-kd secretory protein (sp185) mRNA, partial cds, clone pCt185," April 26, 1993.	
	EC	GenBank Accession No. M24276, DIGNAM et al., "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.1," April 26, 1993.	
	ED	GenBank Accession No. M24277, DIGNAM et al., "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.2," April 26, 1993.	
	EE	GenBank Accession No. D88689, FINNERTY et al., "Mus musculus mRNA for flt-1, complete cds," April 14, 2000.	
	EF	GenBank Accession No. L07296, FINNERTY et al., "Mus musculus receptor tyrosine kinase (FLT4) mRNA, complete cds," August 9, 1993.	
	EG	GenBank Accession No. X54936, MAGLIONE et al., "H.sapiens mRNA for placenta growth factor (PIGF)," November 12, 1991.	
	EH	GenBank Accession No. S57152, MAGLIONE et al., "Homo sapiens placenta growth factor 2 (PIGF-2) gene, partial cds," March 5, 2001.	
	EI	GenBank Accession No. X59397, MATTHEWS et al., "Mouse Flk-1 mRNA for a tyrosine kinase receptor," November 6, 1991.	
	EJ	GenBank Accession No. X52263, PAULSSON et al., "C.tentans balbiani ring 3 (BR3) gene," December 18, 1992.	
	EK	GenBank Accession No. M63971, TISCHER et al., "Human vascular endothelial growth factor gene, exon 1," August, 1993.	
	EL	GenBank Accession No. M63972, TISCHER et al., "Human vascular endothelial growth factor gene, exon 2," August 3, 1993.	
	EM	GenBank Accession No. M63973, TISCHER et al., "Human vascular endothelial growth factor gene, exon 3," August 3, 1993.	
	EN	GenBank Accession No. M63974, TISCHER et al., "Human vascular endothelial growth factor gene, exon 4," August 3, 1993.	
	EO	GenBank Accession No. M63975, TISCHER et al., "Human vascular endothelial growth factor gene, exon 5," August 3, 1993.	

Examiner
Signature

Date
Considered

9/15/03

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900



Please type a plus sign (+) inside this box



Approved for use through 10/31/2002. OMB 0651-0011
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	8	of	9	Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	HU et al.
				Group Art Unit	1647
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M	EP	GenBank Accession No. M63976, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 6," August 3, 1993.	
	EQ	GenBank Accession No. M63977, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 7," August 3, 1993.	
	ER	GenBank Accession No. M63978, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 8," August 3, 1993.	
	ES	GenBank Accession No. M27281, KECK <i>et al.</i> , "Human vascular permeability factor mRNA, complete cds," August 3, 1993.	
	ET	GenBank Accession No. X04571, BELL <i>et al.</i> , "Human mRNA for kidney epidermal growth factor (EGF) precursor," March 21, 1995.	
	EU	GenBank Accession No. X63556, CORSON <i>et al.</i> , "H. sapiens mRNA for fibrillin," February 17, 1997.	
	EV	GenBank Accession No. L19896, CORSON <i>et al.</i> , "Human fibrillin (FBN1) gene, 5' end including alternative exons A, B, and C, and exon M," November 8, 1994.	
	EW	GenBank Accession No. L04947, TERMAN <i>et al.</i> , "Homo sapiens (clones BT3.081.8, BT3.129.5 and BT4.169)," January 6, 1995.	
	EX	GenBank Accession No. M16237, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 2," January 13, 1995.	
	FY	GenBank Accession No. M16243, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 3," January 13, 1995.	
	EZ	GenBank Accession No. M16244, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 4," January 13, 1995.	
	FA	GenBank Accession No. M16245, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 5," January 13, 1995.	
	FB	GenBank Accession No. K03212, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 6," January 13, 1995.	
	FC	GenBank Accession No. K03213, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 7," January 13, 1995.	
	FD	GenBank Accession No. K03214, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 8," January 13, 1995.	
	FE	GenBank Accession No. K03215, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 9," January 13, 1995.	
	FF	GenBank Accession No. K03216, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 10," January 13, 1995.	
	FG	GenBank Accession No. K03217, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 11," January 13, 1995.	

Examiner Signature	<i>[Signature]</i>	Date Considered	7/15/03
--------------------	--------------------	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231



RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known

Application Number	09/935,726
Filing Date	August 24, 2001
First Named Inventor	HU et al.
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	PF112P3D1C1

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M	FH	GenBank Accession No. K03218, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 12," January 13, 1995.	
	FI	GenBank Accession No. M13994, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-alpha protein, complete cds," October 31, 1994.	
	FJ	GenBank Accession No. M13995, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-3-beta protein, complete cds," October 31, 1994.	
	FK	GenBank Accession No. L22473, OLTVAI <i>et al.</i> , "Human Bax alpha mRNA, complete cds," December 15, 1993.	
	FL	GenBank Accession No. L22474, OLTVAI <i>et al.</i> , "Human Bax beta mRNA, complete cds," December 13, 1993.	
	FM	GenBank Accession No. AJ000185, ACHEN <i>et al.</i> , "Homo Sapiens mRNA for vascular endothelial growth factor-D," February 11, 1998.	
	FN	International Search Report, Application No. PCT/US99/05021.	
	FO	International Search Report, Application No. PCT/US94/05291.	

Examiner
Signature

Date
Considered

9-15-03

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

FEB 04 2002

TECH CENTER 1600/2900

RECEIVED

O I P E
JAN 25 2002
PATENT & TRADEMARK OFFICE



RECEIVED

MAR 1 4 2002

Please type a plus sign (+) inside this box ☐

Approved for use through 10/31/02. OMB 05-10801

TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/935,726
				Filing Date	August 24, 2001
				First Named Inventor	Hu, et al.
				Group Art Unit	1647
				Examiner Name	Unassigned <i>Landman</i>
Sheet	1	of	1	Attorney Docket Number	PF112P3D1C1

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
<i>M</i>	FP	EP	0476983	A1	Merck & Co., Inc.	03-25-1992		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	FQ	International Search Report, Application No. PCT/US01/24658 mailed on Dec. 12, 2001.		

Examiner Signature	<i>David</i>	Date Considered	9-15-01
-----------------------	--------------	--------------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.